Results 101 to 110 of about 775,670 (354)

The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population [Corrigendum]

Pharmacogenomics and Personalized Medicine, 2021
Zhang L, Li X, Lu J, et al. Pharmgenomics Pers Med. 2021;14:469–476. Page 470, Materials and Methods, Clinical Samples, second sentence, the text “All blood samples are taken from Liyang People’s Hospital during March 2009 to August ...
Zhang L, Li X, Lu J, Qian Y, Qian T, Wu X, Xu Q   +6 more
doaj  

Activation of different growth factor systems in tissues of adenocarcinoma and signet-ring cell carcinoma of the stomach

Исследования и практика в медицине, 2019
Purpose of the study. The purpose of the study was to find the difference between local levels of VEGF, EGF, IGFI and IG- FII in tumor and intact tissues in adenocarcinoma of the stomach (AC) and signet-ring cell carcinoma of the stomach (SRCC).Materials
O. I. Kit, E. M. Frantsiyants, I. A. Goroshinskaya, E. I. Surikova, V. A. Bandovkina, Yu. A. Pogorelova, L. A. Nemashkalova, D. E. Medvedeva, E. V. Shalashnaja, A. A. Maslov, Yu. S. Sidorenko   +10 more
doaj   +1 more source

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

Ligand-Independent EGFR Signaling [PDF]

Cancer Research, 2015
Abstract Constitutive activation of the EGFR is common in cancer due to EGFR wild-type (EGFRwt) overexpression or the presence of mutant EGFR. Signaling by constitutively active NSCLC EGFR mutants or the EGFRvIII mutant in glioblastoma has been studied intensively and the downstream signals are known.
Gao, Guo, Ke, Gong, Bryan, Wohlfeld, Kimmo J, Hatanpaa, Dawen, Zhao, Amyn A, Habib   +5 more
openaire   +2 more sources

Automatic Classification of Irregularly Sampled Time Series with Unequal Lengths: A Case Study on Estimated Glomerular Filtration Rate

, 2016
A patient's estimated glomerular filtration rate (eGFR) can provide important information about disease progression and kidney function. Traditionally, an eGFR time series is interpreted by a human expert labelling it as stable or unstable.
Bull, Simon, Poh, Norman, Tirunagari, Santosh   +2 more
core   +1 more source

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]

, 2018
Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian, Damman, Kevin, Desai, Akshay S., Gori, Mauro, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Prescott, Margaret F., Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +14 more
core   +4 more sources

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Journal of Clinical Oncology, 2018
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients
T. Reungwetwattana, K. Nakagawa, B. Cho, M. Cobo, E. Cho, A. Bertolini, S. Bohnet, Caicun Zhou, K. Lee, N. Nogami, I. Okamoto, N. Leighl, R. Hodge, A. McKeown, Andrew P. Brown, Y. Rukazenkov, S. Ramalingam, J. Vansteenkiste   +17 more
semanticscholar   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Interpreting eGFR

JMS SKIMS, 2012
Clinical assessment of kidney function is essential for assessing overall health, interpreting signs and symptoms, selecting the correct dosage for renally excreted drugs, preparing for invasive diagnostic or therapeutic procedures, and detecting/ evaluating/ monitoring acute and chronic kidney diseases.
Imtiaz A Wani, Muzafar Maqsood Wani
openaire   +2 more sources